ClinicalTrials.gg
CompletedNCT03386994Updated Nov 9, 2020Results posted

OASIS-IPF (Idiopathic Pulmonary Fibrosis) Study

An observational study in Idiopathic Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Completed at 31 sites in Spain. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2020-11-09.

Sponsored by Boehringer Ingelheim · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
204
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim — 1 open to participants now, 3 under way, 1 of them phase 3. Idiopathic Pulmonary Fibrosis · Boehringer Ingelheim.

Enrollment
10th of 16
204 · median 212
Started
2017
with 3 others
Observational
16 of 36
none open now
Registered
15th of 36
by date

Among the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim, this one is the 10th largest by enrollment of the 16 observational ones that give a count, is one of 4 that started in 2017, is one of 16 observational ones, and was the 15th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

1 of the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim is open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim, or all of them as a file.
02

Study summary

Descriptive prospective non-interventional multicenter study based on newly collected data of Idiopathic Pulmonary Fibrosis patients followed-up for one year in secondary care settings (Pulmonology Services)

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

It is planned that data of approximately 200 patients from approximately 25 sites (secondary care sites - Pulmonology services where IPF is diagnosed and managed) in Spain will be collected. All Idiopathic Pulmonary Fibrosis patients who are diagnosed with IPF and attend to a routine visit during the inclusion period and fulfill inclusion/exclusion criteria and provide informed consent to participate will be included in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female and male patients ≥ 40 years of age
  • Patients diagnosed with Idiopathic Pulmonary Fibrosis (IPF) according to last ATS/ERS/JRS/ALAT IPF guideline for diagnosis and management consensus
  • Written prior to participation

Exclusion criteria

Exclusion Criteria:

  • Inability for the patient to understand or complete the written Inform Consent or patients questionnaires or to understand Spanish
  • Current participation in any clinical trial
  • Patients for whom further follow-up is not possible at the enrolling site
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
204 participants (actual)
Patient registry
No

Groups and cohorts

  • Idiopathic Pulmonary Fibrosis patients

    all IPF patients

06

What researchers measure

Primary outcomes

  1. Idiopathic Pulmonary Fibrosis (IPF)-Related Costs

    The total annual IPF-related costs were obtained as the sum of direct health costs, direct non-health costs and indirect costs. IPF-related costs were quantified for each patient over the follow-up period of 12 months. The direct health and direct non-health costs were calculated as the sum of the costs of medical visits, emergency room visits, hospital admissions, outpatient tests, non-pharmacological treatments and pharmacological treatments and the sum of transport costs, paid caregivers costs, orthopedic material costs, financial aid, and structural changes cost. The indirect costs included number of IPF related days off work and time dedicated to patient care with IPF (informal caregiver). The opportunity cost method was used to calculate informal care costs. The indirect costs were estimated by applying salary costs based on the latest data published by the Spanish Instituto Nacional de Estadística from the salary structure survey, adjusted to age.

    Time frame: 12 months. (At baseline visit (T0), at 6 months visit (T6) and at 12 month visit (T12)).

Secondary outcomes

  1. Quality of Life (QoL) of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through Saint George´s Respiratory Questionaire (SGRQ)

    The Quality of Life of patients with IPF according to Forced Vital Capacity (FVC)% predicted value, is assessed through SGRQ. The SGRQ is a 50-item questionaire developed to quantify the impact of the disease on the health and QoL perceived by patients with respiratory diseases. It consisted of 50 items divided into 3 scales: symptoms (frequency and severity of respiratory symptoms), activity (limitations due to dyspnoea) and impact (psychological and social functioning disorders caused by the disease). The final scores ranged from 0 (best health-related quality of life) to 100 (worse health-related quality of life). The number of participants analysed displays the number of participants with available data at the timepoint of interests.

    Time frame: 12 months. (At baseline visit (T0), at 6 month visit (T6) and at 12 month visit (T12)).

  2. Quality of Life (QoL) of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through EuroQoL Visual Analogue Scale (EQ-VAS)

    The Quality of Life of patients with IPF according to Forced Vital Capacity (FVC)% predicted value is assessed through the EQ-VAS, which is a self-rated health status using a visual analogue scale (VAS), ranging form 0-100, with 0 = worst state of health imaginable and 100 = best state of health imaginable. The EQ-VAS is part of the EuroQoL five dimensions questionaire 5L (EQ-5D-5L). The number of participants analysed displays the number of participants with available data at the timepoint of interests.

    Time frame: 12 months. (At baseline visit (T0), at 6 month visit (T6) and at 12 month visit (T12)).

  3. Quality of Life (QoL) of Patients With Idiopathic Pulmonary Fibrosis (IPF), Through Barthel Index

    The Quality of Life of patients with IPF according to Forced Vital Capacity (FVC)% predicted value is assessed through the Barthel Index. Barthel Index were used to score the ability of a participant to care for himself. It consists of 10 items, the values assigned to each item are based on time and amount of actual physical assistance required if a participant is unable to perform the activity. The final score ranges from 0 and 100. Participant scoring 100 is continent, feeds himself, dresses himself, gets up out of bed and chairs, bathes himself, walks at least a block, and can ascend and descend stairs. The number of participants analysed displays the number of participants with available data at the timepoint of interests.

    Time frame: 12 months. (At baseline visit (T0), at 6 month visit (T6) and at 12 month visit (T12)).

  4. Number of Idiopathic Pulmonary Fibrosis (IPF)-Patients With Acute Exacerbations Along One Year

    Number of IPF-patients with acute exacerbations according to Forced Vital Capacity (FVC)% that occured along one year. Acute exacerbation is defined as an acute, clinically significant respiratory deterioration characterized by evidence of new widespread alveolar abnormality.

    Time frame: 12 months. (At baseline visit (T0), at 6 month visit (T6) and at 12 month visit (T12)).

  5. Total Annual Acute Exacerbation-related Costs

    The total annual acute exacerbation-related costs were obtained as the sum of direct and indirect costs for each patient over the follow-up period of 12 months. For estimation of costs the following variables were used: Acute exacerbation related resource use for direct cost estimation: primary and secondary care visits, emergency visits (primary care and hospital), hospitalizations, ICU with and without intubation (qualitative analysis), outpatient tests and other examinations, use of transport, use of formal caregiver, pharmacological and non-pharmacological treatments (except treatments administered in hospitalization), orthopedic material, formal social services, economic aid and structural adaptations. Acute exacerbation related resource use for indirect cost estimation: patients' days off work and informal caregiver.

    Time frame: 12 months. (At baseline visit (T0), at 6 months visit (T6) at 12 month visit (T12)).

  6. Idiopathic Pulmonary Fibrosis (IPF)-Related Costs by Forced Vital Capacity (FVC) Decline - Overall FVC Patient Group

    Economic Impact of IPF in adult patients through the estimation annual direct and indirect costs associated with the disease (€/year) from a social perspective by FVC decline according to predicted FVC%. FVC decline is calculated: FVC% (T12)- FVC%(T0)). In order to estimate the direct and indirect costs according to FVC decline the following variable were described: FVC predicted along the study. Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years) The calculated variable was stratified into the following subgroups between T0 and T12: ≤-10%; from -10% to -5%; \>-5%

    Time frame: 12 months. (At baseline visit (T0) and at 12 month visit (T12)).

  7. Idiopathic Pulmonary Fibrosis (IPF)-Related Costs by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC<50% at T0

    Economic Impact of IPF in adult patients through the estimation annual direct and indirect costs associated with the disease (€/year) from a social perspective by FVC decline according to predicted FVC%. FVC decline is calculated: FVC% (T12)- FVC%(T0)). In order to estimate the direct and indirect costs according to FVC decline the following variable were described: FVC predicted along the study. Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years) The calculated variable was stratified into the following subgroups between T0 and T12: ≤-10%; from -10% to -5%; \>-5% Results are reported for participants with predicted FVC \<50% at baseline.

    Time frame: 12 months. (At baseline visit (T0) and at 12 month visit (T12)).

  8. Idiopathic Pulmonary Fibrosis (IPF)-Related Costs by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC 50-80% at T0

    Economic Impact of IPF in adult patients through the estimation annual direct and indirect costs associated with the disease (€/year) from a social perspective by FVC decline according to predicted FVC%. FVC decline is calculated: FVC% (T12)- FVC%(T0)). In order to estimate the direct and indirect costs according to FVC decline the following variable were described: Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years) The calculated variable was stratified into the following subgroups between T0 and T12: ≤-10%; from -10% to -5%; \>-5% Results are reported for participants with predicted FVC 50-80% at baseline.

    Time frame: 12 months. (At baseline visit (T0) and at 12 month visit (T12)).

  9. Idiopathic Pulmonary Fibrosis (IPF)-Related Costs by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC>80% at T0

    Economic Impact of IPF in adult patients through the estimation annual direct and indirect costs associated with the disease (€/year) from a social perspective by FVC decline according to predicted FVC%. FVC decline is calculated: FVC% (T12)- FVC%(T0)). In order to estimate the direct and indirect costs according to FVC decline the following variable were described: Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years) The calculated variable was stratified into the following subgroups between T0 and T12: ≤-10%; from -10% to -5%; \>-5% Results are reported for participants with predicted FVC \> 80% at baseline.

    Time frame: 12 months. (At baseline visit (T0) and at 12 month visit (T12)).

  10. Absolute Change in Saint George´s Respiratory Questionaire (SGRQ) Score From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Overall FVC Patient Group

    Absolute Change in SGRQ score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12). The SGRQ is a 50-item questionaire developed to quantify the impact of the disease on the health and QoL perceived by patients with respiratory diseases. It consisted of 50 items divided into 3 scales: symptoms, activity and impact. The final scores ranged from 0 (best health-related quality of life) to 100 (worse health-related quality of life). FVC decline: FVC% (T12)- FVC%(T0) In order to estimate the Quality of Life according to FVC decline the following variable were described: FVC % predicted along the study:. Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years). The calculated variable was stratified into the following subgroups between T0 and T12: ≤-10%; from -10% to -5%; \>-5%

    Time frame: 12 months. (At baseline visit (T0) and at 12 month visit (T12)).

  11. Absolute Change in Saint George´s Respiratory Questionaire (SGRQ) Score From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC<50% at T0

    Absolute Change in SGRQ score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12). The SGRQ is a 50-item questionaire developed to quantify the impact of the disease on the health and QoL perceived by patients with respiratory diseases. It consisted of 50 items divided into 3 scales: symptoms, activity and impact. The final scores ranged from 0 (best health-related quality of life) to 100 (worse health-related quality of life). FVC decline: FVC% (T12)- FVC%(T0) In order to estimate SGRQ according to FVC decline the following variable were described: Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years). The calculated variable was stratified into the following subgroups between T0 and T12: ≤-10%; from -10% to -5%; \>-5% Results are reported for participants with predicted FVC\<50% at baseline.

    Time frame: 12 months. (At baseline visit (T0) and at 12 month visit (T12)).

  12. Absolute Change in Saint George´s Respiratory Questionaire (SGRQ) Score From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC 50-80% at T0

    Absolute Change in SGRQ score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12). The SGRQ is a 50-item questionaire developed to quantify the impact of the disease on the health and QoL perceived by patients with respiratory diseases. It consisted of 50 items divided into 3 scales: symptoms (frequency and severity of respiratory symptoms), activity (limitations due to dyspnoea) and impact (psychological and social functioning disorders caused by the disease). The final scores ranged from 0 (best health-related quality of life) to 100 (worse health-related quality of life). FVC decline: FVC% (T12)- FVC%(T0) Results are reported for participants with predicted FVC 50-80% at baseline.

    Time frame: 12 months (At baseline visit (T0) and at 12 month visit (T12)).

  13. Absolute Change in Saint George´s Respiratory Questionaire (SGRQ) Score From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC>80% at T0

    Absolute Change in SGRQ score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12). The SGRQ is a 50-item questionaire developed to quantify the impact of the disease on the health and QoL perceived by patients with respiratory diseases. It consisted of 50 items divided into 3 scales: symptoms (frequency and severity of respiratory symptoms), activity (limitations due to dyspnoea) and impact (psychological and social functioning disorders caused by the disease). The final scores ranged from 0 (best health-related quality of life) to 100 (worse health-related quality of life). FVC decline: FVC% (T12)- FVC%(T0) Results are reported for participants with predicted FVC \>80% at baseline.

    Time frame: 12 months. (At baseline visit (T0) and at 12 month visit (T12)).

  14. Absolute Change in EuroQoL Visual Analogue Scale (EQ-VAS) From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline- Overall FVC Patient Group

    Absolute Change in EQ-VAS score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12). The EQVAS is a self-rated health status using a VAS (0-100), with 0= worst state of health imaginable and 100= best state of health imaginable. The EQ-VAS records the subject's perceptions of their own current overall health. FVC decline: FVC% (T12)- FVC%(T0) In order to estimate the EQ-VAS according to FVC decline the following variable were described: FVC % predicted along the study: Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years) The calculated variable was stratified into the following subgroups between T0 and T12: ≤-10%; from -10% to -5%; \>-5%

    Time frame: 12 months. (At baseline visit (T0) and at 12 month visit (T12)).

  15. Absolute Change in EuroQoL Visual Analogue Scale (EQ-VAS) From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC<50% at T0

    Absolute Change in EQ-VAS score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12). The EQVAS is a self-rated health status using a VAS (0-100), with 0= worst state of health imaginable and 100= best state of health imaginable. The EQ-VAS records the subject's perceptions of their own current overall health. FVC decline: FVC% (T12)- FVC%(T0) In order to estimate the EQ-VAS according to FVC decline the following variable were described: FVC % predicted along the study: Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years) The calculated variable was stratified into the following subgroups between T0 and T12: ≤-10%; from -10% to -5%; \>-5% Results are reported for participants with predicted FVC\<50% at baseline.

    Time frame: 12 months. (At baseline visit (T0) and at 12 month visit (T12)).

  16. Absolute Change in EuroQoL Visual Analogue Scale (EQ-VAS) From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline- Subgroup: Predicted FVC 50-80% at T0

    Absolute Change in EQ-VAS score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12). The EQVAS is a self-rated health status using a VAS (0-100), with 0= worst state of health imaginable and 100= best state of health imaginable. The EQ-VAS records the subject's perceptions of their own current overall health. FVC decline: FVC% (T12)- FVC%(T0) In order to estimate the EQ-VAS according to FVC decline the following variable were described: FVC % predicted along the study:. Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years) The calculated variable was stratified into the following subgroups between T0 and T12: ≤-10%; from -10% to -5%; \>-5% Results are reported for participants with predicted FVC 50-80% at baseline.

    Time frame: 12 months. (At baseline visit (T0) and at 12 month visit (T12)).

  17. Absolute Change in EuroQoL Visual Analogue Scale (EQ-VAS) From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC>80% at T0

    Absolute Change in EQ-VAS score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12). The EQVAS is a self-rated health status using a VAS (0-100), with 0= worst state of health imaginable and 100= best state of health imaginable. The EQ-VAS records the subject's perceptions of their own current overall health. FVC decline: FVC% (T12)- FVC%(T0) In order to estimate the EQ-VAS according to FVC decline the following variable were described: FVC % predicted along the study:. Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years) The calculated variable was stratified into the following subgroups between T0 and T12: ≤-10%; from -10% to -5%; \>-5% Results are reported for participants with predicted FVC\>80% at baseline.

    Time frame: 12 months. (At baseline visit (T0) and at 12 month visit (T12)).

  18. Impact of Disease on the Patients Caregiver Through Zarit Burden Interview Questionaire

    Caregivers of IPF patients were asked to complete the Zarit Burden Interview. It is a self-report measure. The revised version contains 22 items. Each item on the interview is a statement which the caregiver is asked to endorse using a 5-point scale. Response options, in the Spanish version, range from 0 (never) to 4 (nearly always). The final score ranges from 0 to 88. A higher score implies a greater burden (≤ 21: Little or no burden; 22-40: mild to moderate burden; 41-60: moderate to severe burden; ≥ 61: severe burden).

    Time frame: 12 months. (At baseline visit (T0), at 6 month visit (T6), at 12 month visit (T12)).

07

Results

Posted Oct 5, 2020

Participant flow

Non-interventional multicenter study in Spain, based on newly collected data of patients with Idiopathic Pulmonary Fibrosis (IPF) aims to estimate the economic and social Impact of IPF according to the Forced Vital Capacity (FVC) value.

Participant flow — Overall Study
MilestoneAll Patients With IPF - Overall Population
Started204
Completed166
Not completed38
Withdrew: Lung transplant1
Withdrew: Adverse event14
Withdrew: Lost to follow-up4
Withdrew: Withdrawal by subject3
Withdrew: Death16

Outcome measures

PrimaryIdiopathic Pulmonary Fibrosis (IPF)-Related Costs

The total annual IPF-related costs were obtained as the sum of direct health costs, direct non-health costs and indirect costs. IPF-related costs were quantified for each patient over the follow-up period of 12 months. The direct health and direct non-health costs were calculated as the sum of the costs of medical visits, emergency room visits, hospital admissions, outpatient tests, non-pharmacological treatments and pharmacological treatments and the sum of transport costs, paid caregivers costs, orthopedic material costs, financial aid, and structural changes cost. The indirect costs included number of IPF related days off work and time dedicated to patient care with IPF (informal caregiver). The opportunity cost method was used to calculate informal care costs. The indirect costs were estimated by applying salary costs based on the latest data published by the Spanish Instituto Nacional de Estadística from the salary structure survey, adjusted to age.

Time frame:
12 months. (At baseline visit (T0), at 6 months visit (T6) and at 12 month visit (T12)).
Reported as:
Mean · Euro (€)
Idiopathic Pulmonary Fibrosis (IPF)-Related Costs
Euro (€)IPF Patients With Predicted FVC <50% at T0 - SubgroupIPF Patients With Predicted FVC 50-80% at T0 - SubgroupIPF Patients With Predicted FVC >80% at T0 - Subgroup
Total annual IPF related costs38923.57 ± 29263.4222613.68 ± 12873.0720369.94 ± 11955.91
Annual direct health IPF-related costs37183.17 ± 28465.8622425.64 ± 12788.4220195.31 ± 12159.89
Annual direct non-health related costs1657.63 ± 3148.58149.25 ± 701.58174.63 ± 589.53
Annual indirect IPF-related costs82.77 ± 320.5838.79 ± 316.500.00 ± 0.00
Statistical analysis
  • IPF Patients With Predicted FVC <50% at T0 - Subgroup vs IPF Patients With Predicted FVC 50-80% at T0 - Subgroup vs IPF Patients With Predicted FVC >80% at T0 - Subgroup · ANOVA · p = 0.0002Total annual IPF-related costs
  • IPF Patients With Predicted FVC <50% at T0 - Subgroup vs IPF Patients With Predicted FVC 50-80% at T0 - Subgroup vs IPF Patients With Predicted FVC >80% at T0 - Subgroup · ANOVA · p = 0.0007Annual direct health IPF-related costs
  • IPF Patients With Predicted FVC <50% at T0 - Subgroup vs IPF Patients With Predicted FVC 50-80% at T0 - Subgroup vs IPF Patients With Predicted FVC >80% at T0 - Subgroup · ANOVA · p = <0.0001Annual direct non-health IPF-related costs
  • IPF Patients With Predicted FVC <50% at T0 - Subgroup vs IPF Patients With Predicted FVC 50-80% at T0 - Subgroup vs IPF Patients With Predicted FVC >80% at T0 - Subgroup · ANOVA · p = 0.6839Annual indirect IPF-related costs
SecondaryQuality of Life (QoL) of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through Saint George´s Respiratory Questionaire (SGRQ)

The Quality of Life of patients with IPF according to Forced Vital Capacity (FVC)% predicted value, is assessed through SGRQ. The SGRQ is a 50-item questionaire developed to quantify the impact of the disease on the health and QoL perceived by patients with respiratory diseases. It consisted of 50 items divided into 3 scales: symptoms (frequency and severity of respiratory symptoms), activity (limitations due to dyspnoea) and impact (psychological and social functioning disorders caused by the disease). The final scores ranged from 0 (best health-related quality of life) to 100 (worse health-related quality of life). The number of participants analysed displays the number of participants with available data at the timepoint of interests.

Time frame:
12 months. (At baseline visit (T0), at 6 month visit (T6) and at 12 month visit (T12)).
Reported as:
Mean · Score on a scale
Quality of Life (QoL) of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through Saint George´s Respiratory Questionaire (SGRQ)
Score on a scaleIPF Patients With Predicted FVC <50% at T0 - SubgroupIPF Patients With Predicted FVC 50-80% at T0 - SubgroupIPF Patients With Predicted FVC >80% at T0 - Subgroup
T048.52 ± 17.2633.70 ± 17.1731.97 ± 20.37
T643.34 ± 20.7033.84 ± 19.1530.68 ± 17.98
T1241.64 ± 21.6236.93 ± 19.2725.38 ± 17.38
Statistical analysis
  • IPF Patients With Predicted FVC <50% at T0 - Subgroup vs IPF Patients With Predicted FVC 50-80% at T0 - Subgroup vs IPF Patients With Predicted FVC >80% at T0 - Subgroup · Kruskal-Wallis · p = 0.0020Timepoint: T0
  • IPF Patients With Predicted FVC <50% at T0 - Subgroup vs IPF Patients With Predicted FVC 50-80% at T0 - Subgroup vs IPF Patients With Predicted FVC >80% at T0 - Subgroup · Kruskal-Wallis · p = 0.1385Timepoint: T6
  • IPF Patients With Predicted FVC <50% at T0 - Subgroup vs IPF Patients With Predicted FVC 50-80% at T0 - Subgroup vs IPF Patients With Predicted FVC >80% at T0 - Subgroup · Kruskal-Wallis · p = 0.0233Timepoint: T12
SecondaryQuality of Life (QoL) of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through EuroQoL Visual Analogue Scale (EQ-VAS)

The Quality of Life of patients with IPF according to Forced Vital Capacity (FVC)% predicted value is assessed through the EQ-VAS, which is a self-rated health status using a visual analogue scale (VAS), ranging form 0-100, with 0 = worst state of health imaginable and 100 = best state of health imaginable. The EQ-VAS is part of the EuroQoL five dimensions questionaire 5L (EQ-5D-5L). The number of participants analysed displays the number of participants with available data at the timepoint of interests.

Time frame:
12 months. (At baseline visit (T0), at 6 month visit (T6) and at 12 month visit (T12)).
Reported as:
Mean · Score on a scale
Quality of Life (QoL) of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through EuroQoL Visual Analogue Scale (EQ-VAS)
Score on a scaleIPF Patients With Predicted FVC <50% at T0 - SubgroupIPF Patients With Predicted FVC 50-80% at T0 - SubgroupIPF Patients With Predicted FVC >80% at T0 - Subgroup
T058.41 ± 16.7264.82 ± 20.4366.67 ± 21.39
T659.29 ± 21.1165.16 ± 19.0268.76 ± 19.85
T1263.93 ± 23.9562.91 ± 20.3471.36 ± 17.74
Statistical analysis
  • IPF Patients With Predicted FVC <50% at T0 - Subgroup vs IPF Patients With Predicted FVC 50-80% at T0 - Subgroup vs IPF Patients With Predicted FVC >80% at T0 - Subgroup · Kruskal-Wallis · p = 0.1560 (Timepoint: T0)
  • IPF Patients With Predicted FVC <50% at T0 - Subgroup vs IPF Patients With Predicted FVC 50-80% at T0 - Subgroup vs IPF Patients With Predicted FVC >80% at T0 - Subgroup · Kruskal-Wallis · p = 0.3144 (Timepoint: T6)
  • IPF Patients With Predicted FVC <50% at T0 - Subgroup vs IPF Patients With Predicted FVC 50-80% at T0 - Subgroup vs IPF Patients With Predicted FVC >80% at T0 - Subgroup · Kruskal-Wallis · p = 0.2019 (Timepoint: T12)
SecondaryQuality of Life (QoL) of Patients With Idiopathic Pulmonary Fibrosis (IPF), Through Barthel Index

The Quality of Life of patients with IPF according to Forced Vital Capacity (FVC)% predicted value is assessed through the Barthel Index. Barthel Index were used to score the ability of a participant to care for himself. It consists of 10 items, the values assigned to each item are based on time and amount of actual physical assistance required if a participant is unable to perform the activity. The final score ranges from 0 and 100. Participant scoring 100 is continent, feeds himself, dresses himself, gets up out of bed and chairs, bathes himself, walks at least a block, and can ascend and descend stairs. The number of participants analysed displays the number of participants with available data at the timepoint of interests.

Time frame:
12 months. (At baseline visit (T0), at 6 month visit (T6) and at 12 month visit (T12)).
Reported as:
Mean · Score on a scale
Quality of Life (QoL) of Patients With Idiopathic Pulmonary Fibrosis (IPF), Through Barthel Index
Score on a scaleIPF Patients With Predicted FVC <50% at T0 - SubgroupIPF Patients With Predicted FVC 50-80% at T0 - SubgroupIPF Patients With Predicted FVC >80% at T0 - Subgroup
T092.95 ± 10.7697.50 ± 7.6897.67 ± 5.68
T691.25 ± 12.0895.94 ± 11.2196.35 ± 8.19
T1291.79 ± 15.7695.74 ± 12.6696.59 ± 12.85
Statistical analysis
  • IPF Patients With Predicted FVC <50% at T0 - Subgroup vs IPF Patients With Predicted FVC 50-80% at T0 - Subgroup vs IPF Patients With Predicted FVC >80% at T0 - Subgroup · Kruskal-Wallis · p = 0.0075 (Timepoint: T0)
  • IPF Patients With Predicted FVC <50% at T0 - Subgroup vs IPF Patients With Predicted FVC 50-80% at T0 - Subgroup vs IPF Patients With Predicted FVC >80% at T0 - Subgroup · Kruskal-Wallis · p = 0.0361 (Timepoint: T6)
  • IPF Patients With Predicted FVC <50% at T0 - Subgroup vs IPF Patients With Predicted FVC 50-80% at T0 - Subgroup vs IPF Patients With Predicted FVC >80% at T0 - Subgroup · Kruskal-Wallis · p = 0.4794 (Timepoint: T12)
SecondaryNumber of Idiopathic Pulmonary Fibrosis (IPF)-Patients With Acute Exacerbations Along One Year

Number of IPF-patients with acute exacerbations according to Forced Vital Capacity (FVC)% that occured along one year. Acute exacerbation is defined as an acute, clinically significant respiratory deterioration characterized by evidence of new widespread alveolar abnormality.

Time frame:
12 months. (At baseline visit (T0), at 6 month visit (T6) and at 12 month visit (T12)).
Reported as:
Number · Participants
Number of Idiopathic Pulmonary Fibrosis (IPF)-Patients With Acute Exacerbations Along One Year
ParticipantsIPF Patients With Predicted FVC <50% at T0 - SubgroupIPF Patients With Predicted FVC 50-80% at T0 - SubgroupIPF Patients With Predicted FVC >80% at T0 - Subgroup
Number of Idiopathic Pulmonary Fibrosis (IPF)-Patients With Acute Exacerbations Along One Year6133
Statistical analysis
  • IPF Patients With Predicted FVC <50% at T0 - Subgroup vs IPF Patients With Predicted FVC 50-80% at T0 - Subgroup vs IPF Patients With Predicted FVC >80% at T0 - Subgroup · Fisher Exact · p = 0.0333
SecondaryTotal Annual Acute Exacerbation-related Costs

The total annual acute exacerbation-related costs were obtained as the sum of direct and indirect costs for each patient over the follow-up period of 12 months. For estimation of costs the following variables were used: Acute exacerbation related resource use for direct cost estimation: primary and secondary care visits, emergency visits (primary care and hospital), hospitalizations, ICU with and without intubation (qualitative analysis), outpatient tests and other examinations, use of transport, use of formal caregiver, pharmacological and non-pharmacological treatments (except treatments administered in hospitalization), orthopedic material, formal social services, economic aid and structural adaptations. Acute exacerbation related resource use for indirect cost estimation: patients' days off work and informal caregiver.

Time frame:
12 months. (At baseline visit (T0), at 6 months visit (T6) at 12 month visit (T12)).
Reported as:
Mean · Euro (€)
Total Annual Acute Exacerbation-related Costs
Euro (€)IPF Patients With Predicted FVC <50% at T0 - SubgroupIPF Patients With Predicted FVC 50-80% at T0 - SubgroupIPF Patients With Predicted FVC >80% at T0 - Subgroup
Total Annual Acute Exacerbation-related Costs600.40 ± 1586.20819.28 ± 3827.04142.17 ± 703.24
SecondaryIdiopathic Pulmonary Fibrosis (IPF)-Related Costs by Forced Vital Capacity (FVC) Decline - Overall FVC Patient Group

Economic Impact of IPF in adult patients through the estimation annual direct and indirect costs associated with the disease (€/year) from a social perspective by FVC decline according to predicted FVC%. FVC decline is calculated: FVC% (T12)- FVC%(T0)). In order to estimate the direct and indirect costs according to FVC decline the following variable were described: FVC predicted along the study. Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years) The calculated variable was stratified into the following subgroups between T0 and T12: ≤-10%; from -10% to -5%; \>-5%

Time frame:
12 months. (At baseline visit (T0) and at 12 month visit (T12)).
Reported as:
Mean · Euro (€)
Idiopathic Pulmonary Fibrosis (IPF)-Related Costs by Forced Vital Capacity (FVC) Decline - Overall FVC Patient Group
Euro (€)<-10% FVC DeclineFrom -10 to -5% FVC Decline>-5% FVC Decline
Total annual IPF-related costs22261.30 ± 14568.3820986.06 ± 10864.0826171.47 ± 17009.81
Annual direct health IPF-related costs21926.97 ± 14418.4120939.38 ± 10847.6125818.15 ± 16606.63
Annual direct non-health IPF-related costs331.35 ± 918.610.00 ± 0.00349.66 ± 1511.20
Annual indirect IPF-related costs2.99 ± 14.6346.68 ± 185.743.65 ± 24.86
Statistical analysis
  • <-10% FVC Decline vs From -10 to -5% FVC Decline vs >-5% FVC Decline · ANOVA · p = 0.4711Total annual IPF-related costs
  • <-10% FVC Decline vs From -10 to -5% FVC Decline vs >-5% FVC Decline · ANOVA · p = 0.4095Annual direct health IPF-related costs
  • <-10% FVC Decline vs From -10 to -5% FVC Decline vs >-5% FVC Decline · ANOVA · p = 0.0435Annual direct non-health IPF-related costs
  • <-10% FVC Decline vs From -10 to -5% FVC Decline vs >-5% FVC Decline · ANOVA · p = 0.5479Annual indirect IPF-related costs
SecondaryIdiopathic Pulmonary Fibrosis (IPF)-Related Costs by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC<50% at T0

Economic Impact of IPF in adult patients through the estimation annual direct and indirect costs associated with the disease (€/year) from a social perspective by FVC decline according to predicted FVC%. FVC decline is calculated: FVC% (T12)- FVC%(T0)). In order to estimate the direct and indirect costs according to FVC decline the following variable were described: FVC predicted along the study. Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years) The calculated variable was stratified into the following subgroups between T0 and T12: ≤-10%; from -10% to -5%; \>-5% Results are reported for participants with predicted FVC \<50% at baseline.

Time frame:
12 months. (At baseline visit (T0) and at 12 month visit (T12)).
Reported as:
Mean · Euro (€)
Idiopathic Pulmonary Fibrosis (IPF)-Related Costs by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC<50% at T0
Euro (€)<-10% FVC DeclineFrom -10% to -5% FVC Decline>-5% FVC Decline
Total annual IPF-related costs——48035.14 ± 32937.16
Annual direct health IPF-related costs——45646.56 ± 32130.57
Annual direct non-health related costs——2388.58 ± 3902.02
Annual indirect IPF-related costs——0.00 ± 0.00
SecondaryIdiopathic Pulmonary Fibrosis (IPF)-Related Costs by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC 50-80% at T0

Economic Impact of IPF in adult patients through the estimation annual direct and indirect costs associated with the disease (€/year) from a social perspective by FVC decline according to predicted FVC%. FVC decline is calculated: FVC% (T12)- FVC%(T0)). In order to estimate the direct and indirect costs according to FVC decline the following variable were described: Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years) The calculated variable was stratified into the following subgroups between T0 and T12: ≤-10%; from -10% to -5%; \>-5% Results are reported for participants with predicted FVC 50-80% at baseline.

Time frame:
12 months. (At baseline visit (T0) and at 12 month visit (T12)).
Reported as:
Mean · Euro (€)
Idiopathic Pulmonary Fibrosis (IPF)-Related Costs by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC 50-80% at T0
Euro (€)<-10% FVC DeclineFrom -10% to -5% FVC Decline>-5% FVC Decline
Total annual IPF-related costs24208.51 ± 14372.3820546.19 ± 11062.9223539.60 ± 11999.95
Annual direct health IPF-related costs23826.41 ± 14251.6320490.53 ± 11041.1823450.00 ± 12009.78
Annual direct non-healt IPF-related costs378.68 ± 975.490.00 ± 0.0084.75 ± 574.20
Annual indirect IPF-related costs3.41 ± 15.6455.66 ± 202.194.85 ± 28.60
Statistical analysis
  • <-10% FVC Decline vs From -10% to -5% FVC Decline vs >-5% FVC Decline · ANOVA · p = 0.7486Total annual IPF-related costs
  • <-10% FVC Decline vs From -10% to -5% FVC Decline vs >-5% FVC Decline · ANOVA · p = 0.7652Annual direct health IPF-related costs
  • <-10% FVC Decline vs From -10% to -5% FVC Decline vs >-5% FVC Decline · ANOVA · p = 0.0037Annual direct non-health IPF-related costs
  • <-10% FVC Decline vs From -10% to -5% FVC Decline vs >-5% FVC Decline · ANOVA · p = 0.6119Annual indirect IPF-related costs
SecondaryIdiopathic Pulmonary Fibrosis (IPF)-Related Costs by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC>80% at T0

Economic Impact of IPF in adult patients through the estimation annual direct and indirect costs associated with the disease (€/year) from a social perspective by FVC decline according to predicted FVC%. FVC decline is calculated: FVC% (T12)- FVC%(T0)). In order to estimate the direct and indirect costs according to FVC decline the following variable were described: Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years) The calculated variable was stratified into the following subgroups between T0 and T12: ≤-10%; from -10% to -5%; \>-5% Results are reported for participants with predicted FVC \> 80% at baseline.

Time frame:
12 months. (At baseline visit (T0) and at 12 month visit (T12)).
Reported as:
Mean · Euro (€)
Idiopathic Pulmonary Fibrosis (IPF)-Related Costs by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC>80% at T0
Euro (€)<-10% FVC DeclineFrom -10% to -5% FVC Decline>-5% FVC Decline
Total annual IPF-related costs8630.88 ± 7522.5323273.38 ± 10606.0423810.32 ± 12580.11
Annual direct health IPF-related costs8630.88 ± 7522.5323273.38 ± 10606.0423576.99 ± 13010.66
Annual direct non-health IPF-related costs0.00 ± 0.000.00 ± 0.00233.33 ± 808.29
Annual indirect IPF-related costs0.00 ± 0.000.00 ± 0.000.00 ± 0.00
Statistical analysis
  • <-10% FVC Decline vs From -10% to -5% FVC Decline vs >-5% FVC Decline · ANOVA · p = 0.1581Total annual IPF-related costs
  • <-10% FVC Decline vs From -10% to -5% FVC Decline vs >-5% FVC Decline · ANOVA · p = 0.1581Annual direct health IPF-related costs
  • <-10% FVC Decline vs From -10% to -5% FVC Decline vs >-5% FVC Decline · ANOVA · p = 0.7165Annual direct non-health IPF-related costs
  • <-10% FVC Decline vs From -10% to -5% FVC Decline vs >-5% FVC Decline · ANOVA · p = 1.0000Annual indirect IPF-related costs
SecondaryAbsolute Change in Saint George´s Respiratory Questionaire (SGRQ) Score From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Overall FVC Patient Group

Absolute Change in SGRQ score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12). The SGRQ is a 50-item questionaire developed to quantify the impact of the disease on the health and QoL perceived by patients with respiratory diseases. It consisted of 50 items divided into 3 scales: symptoms, activity and impact. The final scores ranged from 0 (best health-related quality of life) to 100 (worse health-related quality of life). FVC decline: FVC% (T12)- FVC%(T0) In order to estimate the Quality of Life according to FVC decline the following variable were described: FVC % predicted along the study:. Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years). The calculated variable was stratified into the following subgroups between T0 and T12: ≤-10%; from -10% to -5%; \>-5%

Time frame:
12 months. (At baseline visit (T0) and at 12 month visit (T12)).
Reported as:
Mean · Score on a scale
Absolute Change in Saint George´s Respiratory Questionaire (SGRQ) Score From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Overall FVC Patient Group
Score on a scale<-10% FVC DeclineFrom -10% to -5% FVC Decline>-5% FVC Decline
Absolute Change in Saint George´s Respiratory Questionaire (SGRQ) Score From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Overall FVC Patient Group8.49 ± 17.163.20 ± 11.710.23 ± 13.11
Statistical analysis
  • <-10% FVC Decline vs From -10% to -5% FVC Decline vs >-5% FVC Decline · Kruskal-Wallis · p = 0.0733
SecondaryAbsolute Change in Saint George´s Respiratory Questionaire (SGRQ) Score From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC<50% at T0

Absolute Change in SGRQ score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12). The SGRQ is a 50-item questionaire developed to quantify the impact of the disease on the health and QoL perceived by patients with respiratory diseases. It consisted of 50 items divided into 3 scales: symptoms, activity and impact. The final scores ranged from 0 (best health-related quality of life) to 100 (worse health-related quality of life). FVC decline: FVC% (T12)- FVC%(T0) In order to estimate SGRQ according to FVC decline the following variable were described: Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years). The calculated variable was stratified into the following subgroups between T0 and T12: ≤-10%; from -10% to -5%; \>-5% Results are reported for participants with predicted FVC\<50% at baseline.

Time frame:
12 months. (At baseline visit (T0) and at 12 month visit (T12)).
Reported as:
Mean · Score on a scale
Absolute Change in Saint George´s Respiratory Questionaire (SGRQ) Score From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC<50% at T0
Score on a scale<-10% FVC DeclineFrom -10% to -5% FVC Decline>-5% FVC Decline
Absolute Change in Saint George´s Respiratory Questionaire (SGRQ) Score From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC<50% at T0——-14.93 ± 29.03
SecondaryAbsolute Change in Saint George´s Respiratory Questionaire (SGRQ) Score From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC 50-80% at T0

Absolute Change in SGRQ score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12). The SGRQ is a 50-item questionaire developed to quantify the impact of the disease on the health and QoL perceived by patients with respiratory diseases. It consisted of 50 items divided into 3 scales: symptoms (frequency and severity of respiratory symptoms), activity (limitations due to dyspnoea) and impact (psychological and social functioning disorders caused by the disease). The final scores ranged from 0 (best health-related quality of life) to 100 (worse health-related quality of life). FVC decline: FVC% (T12)- FVC%(T0) Results are reported for participants with predicted FVC 50-80% at baseline.

Time frame:
12 months (At baseline visit (T0) and at 12 month visit (T12)).
Reported as:
Mean · Score on a scale
Absolute Change in Saint George´s Respiratory Questionaire (SGRQ) Score From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC 50-80% at T0
Score on a scale<-10% FVC DeclineFrom -10% to -5% FVC Decline>-5% FVC Decline
Absolute Change in Saint George´s Respiratory Questionaire (SGRQ) Score From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC 50-80% at T012.58 ± 14.022.20 ± 12.162.16 ± 9.62
Statistical analysis
  • <-10% FVC Decline vs From -10% to -5% FVC Decline vs >-5% FVC Decline · Kruskal-Wallis · p = 0.0207
SecondaryAbsolute Change in Saint George´s Respiratory Questionaire (SGRQ) Score From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC>80% at T0

Absolute Change in SGRQ score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12). The SGRQ is a 50-item questionaire developed to quantify the impact of the disease on the health and QoL perceived by patients with respiratory diseases. It consisted of 50 items divided into 3 scales: symptoms (frequency and severity of respiratory symptoms), activity (limitations due to dyspnoea) and impact (psychological and social functioning disorders caused by the disease). The final scores ranged from 0 (best health-related quality of life) to 100 (worse health-related quality of life). FVC decline: FVC% (T12)- FVC%(T0) Results are reported for participants with predicted FVC \>80% at baseline.

Time frame:
12 months. (At baseline visit (T0) and at 12 month visit (T12)).
Reported as:
Mean · Score on a scale
Absolute Change in Saint George´s Respiratory Questionaire (SGRQ) Score From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC>80% at T0
Score on a scale<-10% FVC DeclineFrom -10% to -5% FVC Decline>-5% FVC Decline
Absolute Change in Saint George´s Respiratory Questionaire (SGRQ) Score From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC>80% at T0-11.97 ± 19.388.43 ± 8.320.56 ± 6.93
Statistical analysis
  • <-10% FVC Decline vs From -10% to -5% FVC Decline vs >-5% FVC Decline · Kruskal-Wallis · p = 0.0942
SecondaryAbsolute Change in EuroQoL Visual Analogue Scale (EQ-VAS) From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline- Overall FVC Patient Group

Absolute Change in EQ-VAS score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12). The EQVAS is a self-rated health status using a VAS (0-100), with 0= worst state of health imaginable and 100= best state of health imaginable. The EQ-VAS records the subject's perceptions of their own current overall health. FVC decline: FVC% (T12)- FVC%(T0) In order to estimate the EQ-VAS according to FVC decline the following variable were described: FVC % predicted along the study: Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years) The calculated variable was stratified into the following subgroups between T0 and T12: ≤-10%; from -10% to -5%; \>-5%

Time frame:
12 months. (At baseline visit (T0) and at 12 month visit (T12)).
Reported as:
Mean · Score on scale
Absolute Change in EuroQoL Visual Analogue Scale (EQ-VAS) From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline- Overall FVC Patient Group
Score on scale<-10% FVC DeclineFrom -10% to -5% FVC Decline>-5% FVC Decline
Absolute Change in EuroQoL Visual Analogue Scale (EQ-VAS) From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline- Overall FVC Patient Group-8.96 ± 17.74-6.16 ± 18.69-0.04 ± 14.79
Statistical analysis
  • <-10% FVC Decline vs From -10% to -5% FVC Decline vs >-5% FVC Decline · Kruskal-Wallis · p = 0.0747
SecondaryAbsolute Change in EuroQoL Visual Analogue Scale (EQ-VAS) From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC<50% at T0

Absolute Change in EQ-VAS score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12). The EQVAS is a self-rated health status using a VAS (0-100), with 0= worst state of health imaginable and 100= best state of health imaginable. The EQ-VAS records the subject's perceptions of their own current overall health. FVC decline: FVC% (T12)- FVC%(T0) In order to estimate the EQ-VAS according to FVC decline the following variable were described: FVC % predicted along the study: Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years) The calculated variable was stratified into the following subgroups between T0 and T12: ≤-10%; from -10% to -5%; \>-5% Results are reported for participants with predicted FVC\<50% at baseline.

Time frame:
12 months. (At baseline visit (T0) and at 12 month visit (T12)).
Reported as:
Mean · Score on scale
Absolute Change in EuroQoL Visual Analogue Scale (EQ-VAS) From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC<50% at T0
Score on scale<-10% FVC DeclineFrom -10% to -5% FVC Decline>-5% FVC Decline
Absolute Change in EuroQoL Visual Analogue Scale (EQ-VAS) From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC<50% at T0——13.89 ± 13.41
SecondaryAbsolute Change in EuroQoL Visual Analogue Scale (EQ-VAS) From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline- Subgroup: Predicted FVC 50-80% at T0

Absolute Change in EQ-VAS score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12). The EQVAS is a self-rated health status using a VAS (0-100), with 0= worst state of health imaginable and 100= best state of health imaginable. The EQ-VAS records the subject's perceptions of their own current overall health. FVC decline: FVC% (T12)- FVC%(T0) In order to estimate the EQ-VAS according to FVC decline the following variable were described: FVC % predicted along the study:. Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years) The calculated variable was stratified into the following subgroups between T0 and T12: ≤-10%; from -10% to -5%; \>-5% Results are reported for participants with predicted FVC 50-80% at baseline.

Time frame:
12 months. (At baseline visit (T0) and at 12 month visit (T12)).
Reported as:
Mean · Score on scale
Absolute Change in EuroQoL Visual Analogue Scale (EQ-VAS) From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline- Subgroup: Predicted FVC 50-80% at T0
Score on scale<-10% FVC DeclineFrom -10% to -5% FVC Decline>-5% FVC Decline
Absolute Change in EuroQoL Visual Analogue Scale (EQ-VAS) From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline- Subgroup: Predicted FVC 50-80% at T0-10.48 ± 18.21-6.96 ± 20.15-1.45 ± 14.77
Statistical analysis
  • <-10% FVC Decline vs From -10% to -5% FVC Decline vs >-5% FVC Decline · Kruskal-Wallis · p = 0.1282
SecondaryAbsolute Change in EuroQoL Visual Analogue Scale (EQ-VAS) From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC>80% at T0

Absolute Change in EQ-VAS score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12). The EQVAS is a self-rated health status using a VAS (0-100), with 0= worst state of health imaginable and 100= best state of health imaginable. The EQ-VAS records the subject's perceptions of their own current overall health. FVC decline: FVC% (T12)- FVC%(T0) In order to estimate the EQ-VAS according to FVC decline the following variable were described: FVC % predicted along the study:. Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years) The calculated variable was stratified into the following subgroups between T0 and T12: ≤-10%; from -10% to -5%; \>-5% Results are reported for participants with predicted FVC\>80% at baseline.

Time frame:
12 months. (At baseline visit (T0) and at 12 month visit (T12)).
Reported as:
Mean · Score on scale
Absolute Change in EuroQoL Visual Analogue Scale (EQ-VAS) From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC>80% at T0
Score on scale<-10% FVC DeclineFrom -10% to -5% FVC Decline>-5% FVC Decline
Absolute Change in EuroQoL Visual Analogue Scale (EQ-VAS) From Baseline Visit (T0) to 12 Month Visit (T12) by Forced Vital Capacity (FVC) Decline - Subgroup: Predicted FVC>80% at T01.67 ± 10.41-2.00 ± 7.58-2.92 ± 10.54
Statistical analysis
  • <-10% FVC Decline vs From -10% to -5% FVC Decline vs >-5% FVC Decline · Kruskal-Wallis · p = 0.7471
SecondaryImpact of Disease on the Patients Caregiver Through Zarit Burden Interview Questionaire

Caregivers of IPF patients were asked to complete the Zarit Burden Interview. It is a self-report measure. The revised version contains 22 items. Each item on the interview is a statement which the caregiver is asked to endorse using a 5-point scale. Response options, in the Spanish version, range from 0 (never) to 4 (nearly always). The final score ranges from 0 to 88. A higher score implies a greater burden (≤ 21: Little or no burden; 22-40: mild to moderate burden; 41-60: moderate to severe burden; ≥ 61: severe burden).

Time frame:
12 months. (At baseline visit (T0), at 6 month visit (T6), at 12 month visit (T12)).
Reported as:
Mean · Score an a scale
Impact of Disease on the Patients Caregiver Through Zarit Burden Interview Questionaire
Score an a scaleCaregivers
T023.59 ± 15.81
T622.50 ± 17.99
T1222.08 ± 19.45

Adverse events

Collected over From signing informed consent until end of study, up to 12 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Patients With IPF - Overall Population30/204 (14.7%)31/204 (15.2%)12/89 (13.5%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventAll Patients With IPF - Overall Population
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders6/204
Cardio-respiratory arrestCardiac disorders5/204
DeathGeneral disorders3/204
Disease progressionGeneral disorders3/204
Respiratory failureRespiratory, thoracic and mediastinal disorders2/204
Acute myocardial infarctionCardiac disorders1/204
Cardiac failure congestiveCardiac disorders1/204
DiarrhoeaGastrointestinal disorders1/204
AstheniaGeneral disorders1/204
BronchitisInfections and infestations1/204
Most frequent other events
Most frequent other events
EventAll Patients With IPF - Overall Population
DiarrhoeaGastrointestinal disorders12/89

Baseline characteristics

Evaluable Population: All participants who meet the selection criteria (no protocol deviations) and with predicted FVC% classified (in baseline visit). IPF-patients were reported by subgroups (according to predicted FVC at baseline) to make comparisons between groups.

Age, Continuous
Age, Continuous(Years)IPF Patients With Predicted FVC <50% at T0 - SubgroupIPF Patients With Predicted FVC 50-80% at T0 - SubgroupIPF Patients With Predicted FVC >80% at T0 - SubgroupTotal
Mean70.32 ± 8.5271.36 ± 7.2168.33 ± 8.5470.80 ± 7.60
Sex: Female, Male
Sex: Female, Male(Participants)IPF Patients With Predicted FVC <50% at T0 - SubgroupIPF Patients With Predicted FVC 50-80% at T0 - SubgroupIPF Patients With Predicted FVC >80% at T0 - SubgroupTotal
Female4321147
Male1812019157
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)IPF Patients With Predicted FVC <50% at T0 - SubgroupIPF Patients With Predicted FVC 50-80% at T0 - SubgroupIPF Patients With Predicted FVC >80% at T0 - SubgroupTotal
Count of participants———0
08

Study locations

31 sites
  • Hospital General Universitario de Alicante
    Alicante, 03010, Spain
  • Hospital Infanta Cristina
    Badajoz, 06080, Spain
  • Hospital Universitario Cruces
    Barakaldo (Vizcaya), 48903, Spain
  • H. del Mar
    Barcelona, 8003, Spain
  • H. U. Vall d'Hebron
    Barcelona, 8035, Spain
  • H. U. de Bellvitge
    Barcelona, 8907, Spain
  • H. U. Germans Trias i Pujol
    Barcelona, 8916, Spain
  • Hospital Universitario de Burgos
    Burgos, 09006, Spain
  • Hospital General Universitario Santa Lucía
    Cartagena (Murcia), 30202, Spain
  • Hospital General Universitario de Castellón
    Castellón de la Plana, 12004, Spain
  • H. U. de Girona Doctor Josep Trueta
    Girona, 17007, Spain
  • Hospital Universitario Virgen de las Nieves
    Granada, 18014, Spain
  • Can Misses
    Ibiza, 7800, Spain
  • Hospital Universitario Lucus Augusti
    Lugo, 27003, Spain
  • H. Clínico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, 28040, Spain
  • Hospital Universitario Puerta de Hierro
    Majadahonda (Madrid), 28222, Spain
  • H. Son Llatzer
    Mallorca, 7198, Spain
  • H. de Manacor
    Mallorca, 7500, Spain
  • Hospital Costa del Sol
    Marbella (Málaga), 29603, Spain
  • H. Mateu Orfila
    Menorca, 7703, Spain
  • Hospital Montecelo
    Mourente (Pontevedra), 36071, Spain
  • Hospital Regional Universitario de Málaga
    Málaga, 29010, Spain
  • CHU de Ourense
    Ourense, 32005, Spain
  • H. Central de Asturias
    Oviedo, 33011, Spain
  • Hospital Universitari Son Espases
    Palma de Mallorca, 07020, Spain
  • Hospital Universitario Donostia
    San Sebastián, 20014, Spain
  • Complejo Hospitalario Universitario de Santiago
    Santiago de Compostela, 15706, Spain
  • Hospital Sierrallana y Tres Mares
    Torrelavega (Cantabria), 39300, Spain
  • Hospital Clínico Universitario de Valladolid
    Valladolid, 47003, Spain
  • Hospital Miguel Servet
    Zaragoza, 50009, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Sep 2019, 21 months.

Results were first posted in Oct 2020, 1 year after primary completion.

Of 88 observational studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 96. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2017
First posted
Dec 29, 2017
StartActual
Nov 29, 2017
Primary completionActual
Sep 16, 2019
CompletionActual
Sep 16, 2019
Results first posted
Oct 5, 2020
Last update
Nov 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03386994
Responsible party
Sponsor
First posted
Dec 29, 2017
Start date
Nov 29, 2017
Primary completion
Sep 16, 2019
Completion
Sep 16, 2019
Results posted
Oct 5, 2020
Last update
Nov 9, 2020

Study contacts

Mireia Canals, +34607550925
study chair · mireia.canals@boehringer-ingelheim.com

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion